New Zealand markets open in 5 hours 22 minutes

Eli Lilly and Company (LLY)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
901.47+17.59 (+1.99%)
As of 12:38PM EDT. Market open.
Full screen
Loading interactive chart…
  • Yahoo Finance Video

    Eli Lilly seeks to expand Zepbound use to treat sleep apnea

    Eli Lilly (LLY) is reporting success in the use of Zepbound — one of the pharmaceutical giant's landmark GLP-1 weight-loss drugs — to treat sleep apnea. Yahoo Finance Health Reporter Anjalee Khemlani joins The Morning Brief to discuss Eli Lilly's filing for approval from the US Food and Drug Administration (FDA) for this use case and how it may affect makers of CPAP (Continuous Positive Airway Pressure) sleep devices, such as Philips (PHG) and ResMed (RMD). For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.

  • Bloomberg

    Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks

    (Bloomberg) -- The new class of weight-loss drugs are being tested as cure-alls for everything from knee replacements to liver disease and throwing corners of the stock market into disarray.Most Read from BloombergHow Long Can High Rates Last? Bond Markets Say Maybe ForeverJain Raises $5.3 Billion in Biggest Hedge Fund Debut Since 2018Nvidia Sales Grow So Fast That Wall Street Can’t Keep UpBuzzFeed Struggles to Sell Owner of Hit YouTube Show ‘Hot Ones’Volatility Grips Stocks as Nvidia Rout Accel

  • Investor's Business Daily

    Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again

    ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.